

## Supporting information

### Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.


**Emi Shoji<sup>1,2</sup>, Hidetoshi Sakurai<sup>1\*</sup>, Tokiko Nishino<sup>1</sup>, Tatsutoshi Nakahata<sup>1</sup>, Toshio Heike<sup>3</sup>, Tomonari Awaya<sup>3</sup>, Nobuharu Fujii<sup>5</sup>, Yasuko Manabe<sup>5</sup>, Masafumi Matsuo<sup>4</sup>, Atsuko Sehara-Fujisawa<sup>2</sup>**

1. Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
2. Department of Growth Regulation, Institute for Frontier Medical Sciences, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
3. Department of Paediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
4. The Graduate School of Rehabilitation, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan
5. Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, 1-1, Minamiosawa, Hachioji City, Tokyo 192-0397, Japan

\*Corresponding author: Hidetoshi Sakurai



Clinical Application Department, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Tel: +81-075-366-7055; Fax: +81-075-366-7074; Email: [hsakurai@cira.kyoto-u.ac.jp](mailto:hsakurai@cira.kyoto-u.ac.jp)




### Supplementary Figure S1

(a) Morphology of Tet-MyoD transfected hiPS cells derived from 2 different DMD patients, who have deletion in exon 44 (DMD $\Delta 44$ ) and exon 46-47 (DMD $\Delta 46-47$ ) of the *DMD*, and from biological father of DMD $\Delta 44$  (Control, Father) and 201B7 (Control, B7). Scale bar, 200  $\mu$ m. (b) Teratoma formation assay with hematoxylin and eosin staining (HE) and immunohistochemistry, showing ectoderm, mesoderm, and endoderm. Neuronal cells, skeletal muscle cells, and hepatocytes, were detected with Neuron-specific class III beta-tubulin (TUJ1), embryonic myocin heavy chain (eMHC), and albumin, respectively. Tumour sections were prepared from hiPSCs inoculated tibialis anterior (TA) muscles of NOD/scid mice. Arrows indicate endoderm, mesoderm, and ectoderm formed in TA muscles from each hiPSC clones. Scale bar, 100  $\mu$ m.




**a****b****Supplementary Figure S2**

(a) Induction efficiency of tetracycline-mediated mCherry expression in hiPSC clones at day 2 differentiation. (b) Differentiation efficiency were calculated based on MHC positive myotubes/No. of nuclei. Two-way ANOVA demonstrated no significant difference between control and DMD groups based on Scheffé's test.



### Supplementary Figure S3

(a) Representative profile of  $\text{Ca}^{2+}$  influx pattern through Fluo-8 intensity in response to electric stimulation. Electric pulse was applied to cells after 5 sec of stationary phase at a constant frequency of 0.2 Hz at 12 V for one minute. The amplitudes are indicated with double arrowheads. (b) Quantitative analysis of Fluo-8 intensity amplitudes in both Control-Myocytes father and  $\Delta 44$  DMD-Myocytes.  $n = 12$ ,  $**p < 0.01$ . (c) Quantitative analysis of Fluo-8 intensity amplitudes in three clones of Control-Myocytes father and DMD-Myocytes  $\Delta 44$ .  $n = 8$ ,  $**p < 0.01$ .



### Supplementary Figure S4

(a) CK activity was measured after the addition of RR, TRP family channel inhibitor. CK values were normalised with CK value of DMSO treated samples. (b) Images of myotubes with fluorescent Fluo-8 intensity, visualising  $Ca^{2+}$  influx. Scale bar, 200  $\mu m$ . (c)  $Ca^{2+}$  uptake was measured by Fluo-8 intensity in myotubes and quantified. Six myotubes were selected from each Control-, DMD-, and DMD-Myocytes+AO, skeletal muscle cells. Relative fluorescence intensities were normalized to the control intensity in each sample. \*\* $P < 0.01$  Triplicate experiments for each condition.  $n = 3$ .

1 <sup>st</sup> Antibody	Source	Clonarity	Dilution	Company
NCL-DYS1	Mouse	Monoclonal	1/10 (WB)-1/50 (IF)	Leica
NCL-DYS2	Mouse	Monoclonal	1/10	Leica
Dystrophin ab15277	Rabbit	Polyclonal	1/200	Abcam
MHC	Mouse	Monoclonal	1/200	R & D
Skeletal muscle actin	Mouse IgM	Monoclonal	1/200	Acris
CKM	Rabbit	Polyclonal	1/100	Bioworld Technology
TRPV2 (VRL-1)	Rabbit	Polyclonal	1/100	Santa cruz
SSEA4	Mouse	Monoclonal	1/100	Millipore
TRA-1 60	Mouse	Monoclonal	1/100	Millipore
Anti-human nuclei	Mouse	Monoclonal	1/200	Millipore


2 <sup>nd</sup> Antibody	Dilution	Company
Alexa Fluor 488 conjugated goat-anti-mouse IgG	1/500	invitrogen
Alexa Fluor 488 conjugated goat-anti-rabbit IgG	1/500	invitrogen
Alexa Fluor 488 conjugated goat-anti-mouse IgM	1/500	invitrogen
HRP conjugated goat-anti-mouse IgG	1/2000	Vector
HRP conjugated goat-anti-rabbit IgG	1/2000	Vector

**Supplementary Table S1** Primary and secondary antibodies used in this study

	Name		Sequence	Annealing temperature	Cycle	RT
RT-PCR	b-actin	Fw	CTCTTCCAGCCTTCCTTCCT	60 °C	25	
		Rv	CACCTTCACCGTTCAGTTT			
	Dystrophin 43-46	Fw	ACAAAGCTCAGGTCCGATTG		35	
		Rv	AGTTGCTGCTCTTTTCCAGGT			
	Dystrophin 43-48	Fw	ACAAAGCTCAGGTCCGATTG		30	
		Rv	TCCTTCTTGGTTTGGTTGGT			
	Oct3/4	Fw	GACAGGGGGAGGGGAGGAGCTAGG		30	
		Rv	CTTCCCTCCAACCAGTTGCCCAAAC			
Nanog	Fw	CAGCCCCGATTCTTCCACCAGTCCC	30			
	Rv	CGGAAGATTCCCAGTCGGGTTACC				
Sox2	Fw	GGGAAATGGGAGGGGTGAAAAGAGG	30			
	Rv	TTGCGTGAGTGTGGATGGGATTGGTG				
RT-qPCR	b-actin	Fw	CTCTTCCAGCCTTCCTTCC	60 °C	55	Oligo dT
		Rv	CACCTTCACCGTTCAGTTT			
	Oct 3/4	Fw	GACAGGGGGAGGGGAGGAGCTAGG			
		Rv	CTTCCCTCCAACCAGTTGCCCAAAC			
	Sox2	Fw	GGGAAATGGGAGGGGTGAAAAGAGG			
		Rv	TTGCGTGAGTGTGGATGGGATTGGTG			
	Nanog	Fw	CAGCCCCGATTCTTCCACCAGTCCC			
		Rv	CGGAAGATTCCCAGTCGGGTTACC			
	Exo-MyoD	Fw	ACGTGAGGACGAGCATGTG			
		Rv	GTGCAGCGCTTGAGTGTCT			
	Endo-MyoD	Fw	CACTCCGGTCCCAAATGTAG			
		Rv	TTCCCTGTAGCACCACACAC			
	Dystrophin	Fw	GATGCACGAATGGATGACAC			
		Rv	TGTGCTACAGGTGGAGCTTG			
	Myogenin	Fw	TGGGCGTGTAAGGTGTGTAA			
		Rv	CGATGTAAGGTGGACTG			
	CKM	Fw	ACATGGCCAAGGTAAGTACC			
		Rv	TGATGGGGTCAAAGAGTTCC			
	TPM2	Fw	ACGTGAGGACGAGCATGTG			
		Rv	GTGCAGCGCTTGAGTGTCT			
Ubiquitin C	Fw	GTAGTCCCTTCTCGGCGATT				
	RV	TTGTCAAGTGACGATCACAGC				

**Supplementary Table S2** Primers for RT- and qRT-PCR analysis


$\beta$ -actin




Oct3/4



Nanog



Sox2



Lane No.

Ladder (100bp DNA)

1: B7

2: Father


3:  $\Delta 44$

4:  $\Delta 46-47$


**Supplementary Figure Raw data of Figure 1b**




Ladder




Dystrophin (DYS1-Rod)




MHC



Ladder



Dystrophin (DYS2-C)




Lane No.


- 1: B7
- 2: Father
- 3:  $\Delta 44$
- 4:  $\Delta 46-47$

**Supplementary Figure Raw data of Figure 2d**

$\Delta 44$



$\Delta 46-47$



$\beta$ -actin



Lane No.

1: Ladder (100bp DNA)


2: Control

3: DMD

4: +AO


**Supplementary Figure Raw data of Figure 3b**

# $\Delta 44$



Lane No.  
1: Father  
2:  $\Delta 44-1$   
3:  $\Delta 44-1 + AO$


# $\Delta 46-47$




Lane No.  
1: B7  
2:  $\Delta 46-47-1$   
3:  $\Delta 46-47-1 + AO$

Supplementary Figure Raw data of Figure 3c

## Dystrophin 43-46 exon



## $\beta$ -actin



Lane No.

1: Ladder (100bp DNA)

2: Father

3:  $\Delta 44-1$

4:  $\Delta 44-1+CO$

5:  $\Delta 44-1+AO$  200pmol

6:  $\Delta 44-1+AO$  100pmol

7: Negative control

**Supplementary Figure Raw data of Figure 5e**